ThermoGenesis Holdings (NASDAQ:THMO) has filed patent applications
for a point-of-care device which improves the speed and accuracy of
lateral flow immunoassays (LFIA) to detect COVID-19 IgM and IgG
antibodies from a single drop of blood.
The applications have been filed in the U.S. in accordance with the USPTO COVID-19 prioritized examination Pilot Program.
COVID-19 LFIA reader will enable the user to
simply slide the test cartridge into a portable reader, providing an
instant readout which can be recorded into a database, and/or a
cloud-based web portal.
https://seekingalpha.com/news/3582264-thermogenesis-files-patent-applications-for-detection-of-covidminus-19-antibodies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.